3.2 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'F1.129xB6' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
3.2 | | Gm9577 | 'neural stem cell' vs 'niche cell' | cell type | Transcription profiling by high throughput sequencing of three populations of primary dentate gyrus cells |
-3.1 | | Gm9577 | '5 week' vs '1 week' in 'Jak2+/V617F; CRISPR/Cas9 mediated knockout of Dnmt3a' | genotype, time | RNA-seq of Jak2VF LSK cells transduced with Dnmt3a-Cas9-GFP lentivirus vs. emp-Cas9-GFP controls one week and five weeks post methylcellulose plating |
2.6 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'SWR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2.4 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'AKR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2.4 | | Gm9577 | 'ABIN1[D485N] knock-in' vs 'wild type genotype' in 'classical monocyte' | cell type, genotype | RNA-seq of inflammatory monocytes, patrolling monocytes and neutrophils in wild type and ABIN1[D485N] mice |
-2.3 | | Gm9577 | 'neuron' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
2.3 | | Gm9577 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.3 | | Gm9577 | 'SOD1-G93A transgenic' vs 'wild type' at 'day 65' in 'B6/SJL' | genotype, sampling time point, strain | Transcription profiling by high throughput sequencing of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model |
2.2 | | Gm9577 | 'LDB1 knock-down with Ldb1 delta 4/5 construct' vs 'control shRNA' | RNA interference | Role of LDB1 in the transition from chromatin looping to transcription activation |
2.2 | | Gm9577 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'luminal cell of prostate epithelium; Nkx3.1-CreERT2 targeted allele' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
2.1 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in '129S6sv/ev' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2.1 | | Gm9577 | 'Irx3 knockout' vs 'control' at '7 day' | genetic modification, time | RNA-Seq of mouse Irx3-KO and Control ME3 cells on days 1 and 7 of adipogenic differentiation |
2 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'C57BL/6J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'F1.B6x129' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
1.8 | | Gm9577 | 'α-GalCer; 2 microgram' vs 'none' in 'Cd1d homozyous knockout' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |
1.7 | | Gm9577 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'hepatocyte' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
-1.6 | | Gm9577 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
1.6 | | Gm9577 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'A/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
1.5 | | Gm9577 | 'α-GalCer; 2 microgram' vs 'none' in 'wild type genotype' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |
-1.5 | | Gm9577 | 'etoposide; 2.5 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
1.3 | | Gm9577 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
1.2 | | Gm9577 | 'Lymphocytic choriomeningitis mammarenavirus' vs 'none' in 'TRAIL homozygous knock out' | genotype, infect | Comparison of Trail+/+ versus Trail-/- splenic NK cells from naïve and LCMV-infected mice |